Clinical Trial Search

Primary: Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) — -3.44…

Primary: Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients — 20.2; 20.0 Weeks — p==0.74

Primary: Compare the Average Total Improvement Scores at Visits 2 Through 7 During the 6-month Treatment Period Between the Treatment and Placebo Arms — 26.4; 29.3 score on a…

Primary: To Assess the Safety and Tolerability of IMO-8400 in Adult Subjects With DM — 6; 4; 2; 4 participants

Primary: Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI). — 7 Participants

Primary: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) — 21; 37 Participants

Primary: The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3…

Primary: Change From Baseline in Cutaneous Dermatomyositis at 6 Months — -9 units on a scale — p=< .001

Primary: Responder Status Defined as 20% Improvement in at Least 3 Core Set Variables With no More Than 1 of the Remaining Variables, (Muscle Strength Excluded), Worsened by >…

Primary: Change in Calcinosis Activity Visual Analogue Scale Score — -3.45 Units on a scale

Primary: Number of Patients Meeting the Definition of Improvement (DOI) at Week 24: at Least 3 of 6 Core Set Measures (CSM) Improved by ≥ 20% With no More Than 2 CSM Worsening by…

Primary: The Primary Endpoint is the Total Dose of Glucocorticoids Administered Between Baseline and the End of Treatment. — 124; 135 mg/kg

Primary: Occurrence of at Least One Adverse Event — 1; 1; 5; 1 participants

Primary: Number of Participants Achieving International Myositis Assessment and Clinical Studies Definition of Improvement (IMACS DOI) at Week 24 Without Rescue — 42; 31…

Primary: Overall Survival — 88.0 percentage of participants

Primary: Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Severity as Measured by a Difference in Physician Calcinosis Visual Analog Scales…

Primary: Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment Period — 25.5; 25.0; 33.1; 33.5 score on a scale

Primary: % Predicted Forced Vital Capacity (FVC) Absolute Change — -1.70; -2.05 % predicted FVC — p=<0.05

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 101; 27 participants

Primary: Count of Adverse Events Reported — 109; 52 adverse events reported

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 7; 13; 20 Participants

Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24

Primary: Response Rate During Randomized Phase — 3; 1; 5; 2 Participants — p=0.60

Primary: Mean Total Improvement Score (TIS) at OLE Week 48 — 36.4 score on a scale

Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline

Primary: Change From Baseline to Week 24 in Distance Walked as Assessed by the Six-minute Walk Test (6MWT) Distance — 12.40; 20.11 meters

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 3; 6; 6; 5 Participants

Primary: Number of Participants Experiencing Adverse Events When Treated With S48168 (ARM210) — 0; 0; 0; 0 Participants

Primary: Number of Responders With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR 20/50/70 Responders) — 12; 7; 5; 15 participants

Primary: Time to Treatment Failure — 0; 8 participants